Tag: Dr Daniel Adelman
Study Shows Negative Impact of Avoidance and Fear of Accidental Reactions...
The psychosocial impact of food allergies on children and teens is severe.
Results of Aimmune’s Pivotal Phase 3 European Trial of PALFORZIA® Published...
Peanut-allergic patients treated with Palforzia showed desensitization to peanut protein with a predictable safety profile at nine months
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued...
After 2 Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels.
Phase 3 Trial Data Demonstrates Consistent Safety and Efficacy of AR101...
“Results of the European ARTEMIS trial provide further clinical validation of the safety and efficacy of AR101 for children and adolescents with peanut allergy.”
European Phase 3 Trial of AR101 Peanut OIT Candidate Meets Primary...
Company Intends to Submit European MAA in Mid-2019.
Aimmune Therapeutics Presents New AR101 Data Including Demonstrated Reduction in Accidental...
AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any Dose of Peanut Protein in Exit Challenge Compared to Placebo.
